Search results
Results from the WOW.Com Content Network
Fibromyalgia is estimated to affect 2 to 4% of the population. [13] Women are affected more than men. [4] [13] Rates appear similar across areas of the world and among varied cultures. [4] Symptoms of fibromyalgia are persistent in nearly all patients. [14] The treatment of fibromyalgia is symptomatic [15] and multidisciplinary. [16]
Post-exertional malaise (PEM), sometimes referred to as post-exertional symptom exacerbation (PESE) [1] or post-exertional neuroimmune exhaustion (PENE), [2] is a worsening of symptoms that occurs after minimal exertion. It is the hallmark symptom of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and common in long COVID and ...
The National Fibromyalgia Association (NFA) is a nonprofit organization whose purpose is to help improve the quality of life for people living with fibromyalgia (FM) and other chronic pain conditions. The NFA has worked to build international awareness of this chronic pain disorder, provide patient assistance and support, educate the medical ...
Guaifenesin. Guaifenesin protocol is an unapproved treatment for fibromyalgia suggested in the 1990s by R. Paul St. Amand, M.D.The protocol involves three parts: titrating the guaifenesin dosage, avoiding salicylates, and following a low-carbohydrate diet if the patient is hypoglycemic.
In 2008 a randomised double-blind placebo-controlled six-month trial on 96 aged subjects with CFS symptoms administering acetyl L-carnitine was reported. By the end of the treatment, significant differences between the two groups were found for both physical and mental fatigue and improvements in both the cognitive status and physical functions ...
Treatment with oral tyrosine kinase inhibitor drugs (e.g. imatinib, sorafenib, pazopanib, sunitinib) shows promising success rates. [43] [29] [44] [40] [45] Radiation therapy after surgery may improve outcomes. [15] [45] Despite the condition's hormonal link, anti-hormonal therapies only appear to work in a small subset of patients. [15]
Oral submucous fibrosis (OSF) is a chronic, complex, premalignant (1% transformation risk) condition of the oral cavity, characterized by juxta-epithelial inflammatory reaction and progressive fibrosis of the submucosal tissues (the lamina propria and deeper connective tissues).
The primary treatment for PF/PM lesions is watchful waiting, i.e. following the lesions for spontaneous regression or any possible complications that require surgical intervention. Symptomatic therapy such as analgesics, e.g. nonsteroidal anti-inflammatory drugs , may be required to treat pain or rare cases of fever. [ 1 ]